布地奈德福莫特罗联合噻托溴铵治疗COPD合并慢性呼吸衰竭疗效观察

Combination of Inhaled Budesonide/Bormoterol and Tiotropium in Treatment of the Stable COPD Patients With Chronic Respiratory Failure

目的 观察布地奈德福莫特罗与噻托溴铵联合吸入对合并慢性呼吸衰竭的慢性阻塞性肺疾病（COPD）稳定期患者的疗效。方法 选取2011年1月~2013年12月于本院呼吸科门诊就诊的90例合并慢性呼吸衰竭的稳定期COPD患者,采用完全随机法分成3组（即布地奈德福莫特罗组、噻托溴铵组、布地奈德福莫特罗与噻托溴铵联合组）,共治疗6个月。分别于治疗前和治疗后测定患者肺功能（FEV1%）、动脉血气分析,记录慢性阻塞性肺疾病评估测试量表评分及半年内急性加重次数。结果 布地奈德福莫特罗组和噻托溴铵组肺功能（FEV1%）、血气分析,慢性阻塞性肺疾病评估测试量表评分较治疗前改善（P〈0.05）,联合组各项指标改善优于其他两组（P〈0.05）。联合组急性加重次数较其余两组减少（P〈0.05）。结论 布地奈德福莫特罗及噻托溴铵联合吸入对合并慢性呼吸衰竭的COPD稳定期患者疗效肯定,优于单一药物治疗。

Objective To evaluate the effects of the combination treatment of budesonide/formoterol and tiotropium in stable COPD patients with chronic respiratory failure. Methods 90 patients with stable COPD combined chronic respiratory failure were recruited from January 2011 to December 2013 in our hospital. The patients were randomly divided into three groups（Budesonide/formoterol group,Tiotropium group and combination group）. All patients had received treatment for 6 months.Before and after the treatment,lung function（FEV1%）,blood gas analysis（PO2 and PCO2）,chronic obstructive pulmonary disease assessment test（CAT） score were assessed. The number of exacerbations were also recorded during 6 months.Results Lung function, blood gas analysis,and the CAT score were improved in all groups compared with baseline（P〈0.05）,especially in the combination group（P〈0.05）. Compared with the Budesonide/formoterol group and the Tiotropium group,the combination therapy significantly decreased the incidence of exacerbations（P〈0.05）. Conclusion Budesonide/formoterol combined Tiotropium is effective for the treatment of stable COPD patients with chronic respiratory failure,which is better than a single drug treatment.